文献速递泌尿男性生殖肿瘤

新型4-miRNA比值模型MiCaP在前列腺癌术后结局预测中的训练与验证

Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients.
PubMed 文献 · Ann Oncol · 2018-01-01

研究通过对123例根治性前列腺切除术(RP)患者组织进行全基因组miRNA表达谱分析,训练出4-miRNA比值模型MiCaP,并在两个独立队列(PCA352和PCA476,总计>800例RP患者)中验证。MiCaP可独立于常规临床病理变量预测生化复发(BCR),且与前列腺癌特异性生存(CSS)显著相关。

要点

  • MiCaP模型由四种miRNA比值构成,无需额外归一化。
  • 在三个RP队列中独立预测BCR,并显著预测CSS。
  • 血浆MiCaP高分与BCR显著相关,展现液体活检潜力。

核心结论

  • MiCaP是一种新型4-miRNA比值模型,在三个RP队列中具有显著的独立预后价值,有望改善前列腺癌风险分层。

研究设计与样本

  • 训练队列为123例接受RP的前列腺癌患者组织样本(PCA123),通过全基因组miRNA表达谱筛选候选miRNA。
  • 验证队列为两个独立RP队列(PCA352和PCA476),总计超过800例患者。
  • 终点为生化复发(BCR)和前列腺癌特异性生存(CSS),采用Cox回归和Kaplan-Meier分析。

主要发现

  • MiCaP模型为(miR-23a-3p×miR-10b-5p)/(miR-133a×miR-374b-5p),在训练队列中独立于常规临床病理变量预测BCR时间。
  • MiCaP在单变量分析中显著预测CSS:HR 3.35(95% CI 1.34-8.35),P=0.0096。
  • MiCaP在多变量分析中显著预测CSS:HR 2.43(95% CI 1.45-4.07),P=0.0210。
  • 在111例RP患者血浆样本中,高MiCaP评分与BCR显著相关(P=0.0036,Kaplan-Meier分析)。

临床怎么用

  • MiCaP可作为术后风险分层的分子工具,辅助识别高BCR风险患者。
  • 血浆MiCaP检测可能成为微创监测手段,但需进一步验证。

局限性

  • 研究队列死亡率较低(CSS事件率5.4%),可能影响CSS分析的稳健性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: New molecular biomarkers for prostate cancer (PC) prognosis are urgently needed. Ratio-based models are attractive, as they require no additional normalization. Here, we train and independently validate a novel 4-miRNA prognostic ratio model for PC. PATIENTS AND METHODS: By genome-wide miRNA expression profiling of PC tissue samples from 123 men who underwent radical prostatectomy (RP) (PCA123, training cohort), we identified six top candidate prognostic miRNAs and systematically tested their ability to predict postoperative biochemical recurrence (BCR). The best miRNA-based prognostic ratio model (MiCaP) was validated in two independent cohorts (PCA352 and PCA476) including >800 RP patients in total. Clinical end points were BCR and prostate cancer-specific survival (CSS). The prognostic potential of MiCaP was assessed by univariate and multivariate Cox-regression analyses and Kaplan-Meier analyses. RESULTS: We identified a 4-miRNA ratio model, MiCaP (miR-23a-3p×miR-10b-5p)/(miR-133a×miR-374b-5p), that predicted time to BCR independently of routine clinicopathologic variables in the training cohort (PCA123) and was successfully validated in two independent RP cohorts. In addition, MiCaP was a significant predictor of CSS in univariate analysis [HR 3.35 (95% CI 1.34 - 8.35), P = 0.0096] and in multivariate analysis [HR 2.43 (95% CI 1.45-4.07), P = 0.0210]. As proof-of-principle, we also analyzed MiCaP in plasma samples from 111 RP patients. A high MiCaP score in plasma was significantly associated with BCR (P = 0.0036, Kaplan-Meier analysis). Limitations include low mortality rates (CSS: 5.4%). CONCLUSIONS: We identified a novel 4-miRNA ratio model (MiCaP) with significant independent prognostic value in three RP cohorts, indicating promising potential to improve PC risk stratification.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Schmidt L, Fredsøe J, Kristensen H, et al. Training and validation of a novel 4-miRNA ratio model (MiCaP) for prediction of postoperative outcome in prostate cancer patients. Ann Oncol. 2018. PMID: 30010760. doi:10.1093/annonc/mdy243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。